153 related articles for article (PubMed ID: 23086641)
41. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
42. Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway.
Wu DP; Zhou Y; Hou LX; Zhu XX; Yi W; Yang SM; Lin TY; Huang JL; Zhang B; Yin XX
Int J Biol Sci; 2021; 17(10):2380-2398. PubMed ID: 34326682
[TBL] [Abstract][Full Text] [Related]
43. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
44. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
45. Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.
Xu HY; Chen ZW; Hou JC; Du FX; Liu JC
Oncol Rep; 2013 Jan; 29(1):212-8. PubMed ID: 23129237
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
47. [Effect of Astragalus mongholicus injection on proliferation and apoptosis of hormone sensitive (MCF-7) breast cancer cell lines with physiological dose E2].
Zhou RF; Liu PX; Tan M
Zhong Yao Cai; 2009 May; 32(5):744-7. PubMed ID: 19771851
[TBL] [Abstract][Full Text] [Related]
48. Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis.
Chang X; Liu Z; Cao S; Bian J; Zheng D; Wang N; Guan Q; Wu Y; Zhang W; Li Z; Zuo D
Toxicol Appl Pharmacol; 2022 Feb; 436():115883. PubMed ID: 35031325
[TBL] [Abstract][Full Text] [Related]
49. Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer.
Wu M; Ding J; Wen L; Zhou Y; Wu W
Biomed Res Int; 2021; 2021():6618519. PubMed ID: 33816619
[TBL] [Abstract][Full Text] [Related]
50. [Effect of sodium aescinate in inducing human breast cancer MCF-7 cells apoptosis by inhibiting AKT, ERK and upstream signal SRC activity].
Qi SM; Lv J; Meng Y; Qi ZL; Ling LF
Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(16):3267-72. PubMed ID: 26790305
[TBL] [Abstract][Full Text] [Related]
51. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
[TBL] [Abstract][Full Text] [Related]
52. Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.
Wang LJ; Han SX; Bai E; Zhou X; Li M; Jing GH; Zhao J; Yang AG; Zhu Q
Oncol Rep; 2013 Apr; 29(4):1563-9. PubMed ID: 23338782
[TBL] [Abstract][Full Text] [Related]
53. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
54. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells.
Ignatov A; Ignatov T; Roessner A; Costa SD; Kalinski T
Breast Cancer Res Treat; 2010 Aug; 123(1):87-96. PubMed ID: 19911269
[TBL] [Abstract][Full Text] [Related]
55. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
56. [Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway].
Chu ZH; Liang XH; Zhou XL; Huang RF; Zhan Qz; Jiang JW
Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):533-8. PubMed ID: 21565140
[TBL] [Abstract][Full Text] [Related]
57. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
58. Quercetin reverses tamoxifen resistance in breast cancer cells.
Wang H; Tao L; Qi K; Zhang H; Feng D; Wei W; Kong H; Chen T; Lin Q
J BUON; 2015; 20(3):707-13. PubMed ID: 26214621
[TBL] [Abstract][Full Text] [Related]
59. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
